Intraocular Inflammation Following Intravitreal Injection of Anti-VEGF Medications for Neovascular Age-Related Macular Degeneration
Open Access
- 3 March 2016
- journal article
- editorial
- Published by Taylor & Francis in Ophthalmic Epidemiology
- Vol. 23 (2) , 69-70
Abstract
Intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents has become routine in the management of neovascular age-related macular degeneration (nAMD), diabetic macular edema, ...Keywords
This publication has 7 references indexed in Scilit:
- Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database AnalysisOphthalmic Epidemiology, 2016
- Global reported endophthalmitis risk following intravitreal injections of anti-VEGF: a literature review and analysisClinical Ophthalmology, 2015
- Postmarketing Analysis of Aflibercept-Related Sterile Intraocular InflammationJAMA Ophthalmology, 2015
- Postinjection Endophthalmitis in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT)Ophthalmology, 2015
- Meta-Analysis of Infectious Endophthalmitis After Intravitreal Injection of Anti-Vascular Endothelial Growth Factor AgentsOphthalmic Surgery, Lasers and Imaging Retina, 2014
- Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular DegenerationOphthalmology, 2012
- Ranibizumab versus Verteporfin for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006